Evaluation of β1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer
- 1 September 2002
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 187 (3), 575-580
- https://doi.org/10.1067/mob.2002.125888
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Human ovarian cancer, lymphoma spleen, and bovine milk GlcNAc:β1,4Gal/GalNAc transferases: two molecular species in ovarian tumor and induction of GalNAcβ1,4Glc synthesis by α-lactalbuminCarbohydrate Research, 2001
- Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?Gynecologic Oncology, 1990
- GlycosyltransferasesJournal of Biological Chemistry, 1989
- Serum β-(1→4)-galactosyltransferase activity with synthetic low molecular weight acceptor in human ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1987
- CA 125 Serum Levels Correlated With Second-Look Operations Among Ovarian Cancer PatientsObstetrics & Gynecology, 1986
- Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1985
- Serum galactosyltransferase isoenzymes as markers for solid tumours in humansEuropean Journal of Cancer and Clinical Oncology, 1984
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- Cell Surface Glycosyltransferase ActivitiesInternational Review of Cytology, 1980
- Determination of serum galactosyltransferase levels in ovarian cancer patients for the evaluation of the effectiveness of therapeutic programsCancer Letters, 1980